Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Rating of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been assigned an average recommendation of “Hold” from the five research firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $20.3333.

Several equities analysts have commented on the stock. HC Wainwright lifted their target price on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings lowered Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Ascendiant Capital Markets decreased their price target on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th. Finally, Rodman & Renshaw assumed coverage on Atossa Genetics in a report on Tuesday. They set a “buy” rating and a $12.00 price target on the stock.

Atossa Genetics Price Performance

Shares of NASDAQ ATOS traded up $0.01 during trading on Tuesday, hitting $2.29. The stock had a trading volume of 97,073 shares, compared to its average volume of 138,711. The firm has a fifty day moving average of $4.00 and a two-hundred day moving average of $5.72. The company has a market capitalization of $19.72 million, a PE ratio of -0.71 and a beta of 1.25. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $19.35.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). On average, equities analysts expect that Atossa Genetics will post -4.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atossa Genetics

Hedge funds have recently made changes to their positions in the business. Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics in the second quarter valued at approximately $26,000. JPMorgan Chase & Co. boosted its holdings in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after buying an additional 35,474 shares during the period. &PARTNERS purchased a new position in Atossa Genetics in the 4th quarter valued at approximately $25,000. Bank of America Corp DE grew its stake in Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after acquiring an additional 144,412 shares during the period. 12.74% of the stock is currently owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.